{"analyses":[{"ciPctValue":"95","groupDescription":"Comparing all three treatment groups","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0004","pValueComment":"The Closure Principle was used to adjust for multiple comparisons. This was a secondary endpoint in a hierarchical testing structure.","statisticalMethod":"Kruskal-Wallis"},{"ciPctValue":"95","groupDescription":"Rituximab 2 x 0.5 g + Methotrexate versus Placebo + Methotrexate, stratified for region and baseline RF status","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1194","pValueComment":"The Closure Principle was used to adjust for multiple comparisons. This was a secondary endpoint in a hierarchical testing structure.","statisticalMethod":"Van-Elteren"},{"ciPctValue":"95","groupDescription":"Rituximab 2 x 1.0 g + Methotrexate versus Placebo + Methotrexate, stratified for region and baseline RF status","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0001","pValueComment":"The Closure Principle was used to adjust for multiple comparisons. This was a secondary endpoint in a hierarchical testing structure.","statisticalMethod":"Van-Elteren"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.0480","value":"0.738"},{"groupId":"OG001","spread":"1.2065","value":"0.453"},{"groupId":"OG002","spread":"0.6252","value":"0.233"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"232"},{"groupId":"OG001","value":"239"},{"groupId":"OG002","value":"244"}],"units":"Participants"}],"description":"Rate of progression in structural joint damage (PJD) by change in modified Sharp erosion score from screening to Week 52. The ES is the sum of joint scores collected for 46 joints and has a range of 0 to 230. A score of 0 would indicate no change and higher scores represent a worsening of joint erosions.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo intravenously on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.\n\nFrom Week 104 participants were eligible to receive Rituximab 2 X 0.5 g or Rituximab 2 X 1.0 g every 24 weeks.","id":"OG000","title":"Placebo + Methotrexate"},{"description":"Rituximab intravenously at a dose of 0.5 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.\n\nSubsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6","id":"OG001","title":"Rituximab (0.5 g x 2) + Methotrexate"},{"description":"Rituximab intravenously at a dose of 1.0 g on Days 1 and 15 + a background of methotrexate orally at a dose of 7.5 mg escalating by 2.5 mg a week every 1-2 weeks to achieve: 15 mg per week by Week 4 and 20 mg per week by Week 8.\n\nSubsequent Rituximab treatment courses were given at 24 week intervals for 5 years provided the Disease Activity Score 28 Joint Count- Erythrocyte Sedimentation Rate (DAS-ESR) result was ≥2.6","id":"OG002","title":"Rituximab (1.0 g x 2) + Methotrexate"}],"paramType":"MEAN","populationDescription":"Modified intent-to-treat population includes patients with a screening and at least one post-baseline radiographic evaluation, grouped as randomized. Linear interpolation/extrapolation used for missing data.","reportingStatus":"POSTED","timeFrame":"Baseline and week 52","title":"Change From Baseline in Modified Sharp Erosion Score at Week 52","type":"SECONDARY","unitOfMeasure":"Score on a scale"}